6:31AM Alexion Pharma: FDA grants priority review for sBLA for Soliris as a treatment for patients with Atypical Hemolytic Uremic Syndrome (ALXN) 47.42 : Co announces that the FDA granted the co's request for Priority Review of its supplemental Biologics License Application) for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome. A Priority Review designation is given to drugs that may offer major advances in treatment, or provide a treatment where no adequate therapy exists. If approval is granted, co anticipates that Soliris would be available for U.S. patients with aHUS in the fourth quarter of 2011.
Market Data 
Markets 
AI
